Sarcopenia and cachexia in the era of obesity: Clinical and nutritional impact

Proceedings of the Nutrition Society

Volumn 75, Issue 2, 2016, Pages 188-198

  Prado, C M ^a   Cushen, S J ^b   Orsso, C E ^a   Ryan, A M ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

Body composition; Cancer; Lean body mass; Lean soft tissue; Muscle; Nutritional assessment; Nutritional status; Obesity; Sarcopenia; Sarcopenic obesity

Indexed keywords

CAPECITABINE; CISPLATIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROPYRIMIDINE; FLUOROURACIL; IMATINIB; SORAFENIB; SUNITINIB; VANDETANIB; PROTEIN INTAKE;

ADIPOSE TISSUE; ADJUVANT THERAPY; ARTICLE; BODY COMPOSITION; BODY MASS; BREAST CANCER; CACHEXIA; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CATABOLISM; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; DIET THERAPY; DRUG SAFETY; ESOPHAGOGASTRIC CANCER; GASTROINTESTINAL STROMAL TUMOR; HUMAN; IMAGE ANALYSIS; KIDNEY CANCER; MUSCLE; MUSCLE MASS; NUTRITION; OBESITY; SARCOPENIA; STOMACH CANCER; THYROID MEDULLARY CARCINOMA; WEIGHT REDUCTION; ADMINISTRATION AND DOSAGE; CALORIC INTAKE; NEOPLASMS; NUTRITIONAL ASSESSMENT; NUTRITIONAL REQUIREMENT; PROCEDURES; PROTEIN INTAKE; SKELETAL MUSCLE;

ADIPOSE TISSUE; BODY COMPOSITION; BODY MASS INDEX; CACHEXIA; DIETARY PROTEINS; ENERGY INTAKE; HUMANS; MUSCLE, SKELETAL; NEOPLASMS; NUTRITION ASSESSMENT; NUTRITION THERAPY; NUTRITIONAL PHYSIOLOGICAL PHENOMENA; NUTRITIONAL REQUIREMENTS; OBESITY; SARCOPENIA;

EID: 84953239594     PISSN: 00296651     EISSN: 14752719     Source Type: Journal    
DOI: 10.1017/S0029665115004279     Document Type: Article

References (82)

1. Schols AM (2015) Nutritional advances in patients with respiratory diseases. Eur Respir Rev 24, 17-22.
2. Sheean PM, Peterson SJ, Gomez Perez S et al. (2014) The prevalence of sarcopenia in patients with respiratory failure classified as normally nourished using computed tomography and subjective global assessment. JPEN J Parent Enteral Nutr 38, 873-879.
3. Staal-van den Brekel AJ, Schols AM &Dentener MA (1997) Metabolism in patients with small cell lung carcinoma compared with patients with non-small cell lung carcinoma and healthy controls. Thorax 52, 338-341.
4. Montano-Loza AJ, Meza-Junco J, Prado CM et al. (2012) Muscle wasting is associated with mortality in patients with cirrhosis. Clin Gastroenterol Hepatol 10, 166-173, 73e1.
5. Montano-Loza AJ, Angulo P, Meza-Junco J et al. (2015) Sarcopenic obesity and myosteatosis are associated with higher mortality in patients with cirrhosis. J Cachexia, Sarcopenia Muscle (epublication ahead of print version)
6. Roubenoff R (2000) Sarcopenic obesity: does muscle loss cause fat gain? Lessons from rheumatoid arthritis and osteoarthritis. Ann N Y Acad Sci 904, 553-557.
7. Wannamethee SG &Atkins JL (2015) Muscle loss and obesity: the health implications of sarcopenia and sarcopenic obesity. Proc Nutr Soc 74, 405-412.
8. Baracos VE (2006) Cancer-associated cachexia and underlying biological mechanisms. Annu Rev Nutr 26, 435-461.
9. Martin L, Senesse P, Gioulbasanis I et al. (2015) Diagnostic criteria for the classification of cancerassociated weight loss. J Clin Oncol 33, 90-99.
10. Prado CM, Lieffers JR, McCargar LJ et al. (2008) Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol 9, 629-635.
11. Prado CM &Heymsfield SB (2014) Lean tissue imaging: a new era for nutritional assessment and intervention. JPEN J Parent Enteral Nutr 38, 940-953.
12. Prado CM, Birdsell LA &Baracos VE (2009) The emerging role of computerized tomography in assessing cancer cachexia. Curr Opin Support Palliat Care 3, 269-275.
13. Shen W, Punyanitya M, Wang Z et al. (2004) Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. J Appl Physiol 97, 2333-2338.
14. Chung H, Cobzas D, Lieffers JR et al. (2009) Muscle and adipose tissue segmentation in CT images. Automated Segmentation of Muscle and Adipose Tissue on CT Images for Human Body Composition Analysis 7261.
15. Mitsiopoulos N, Baumgartner RN, Heymsfield SB et al. (1998) Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography. J Appl Physiol 85, 115-122.
16. Miller KD, Jones E, Yanovski JA et al. (1998) Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 351, 871-875.
17. Lieffers JR, Bathe OF, Fassbender K et al. (2012) Sarcopenia is associated with postoperative infection and delayed recovery from colorectal cancer resection surgery. Br J Cancer 107, 931-936.
18. Baracos VE, Reiman T, Mourtzakis M et al. (2010) Body composition in patients with non-small cell lung cancer: a contemporary view of cancer cachexia with the use of computed tomography image analysis. Am J Clin Nutr 91, 1133S-1137S.
19. Cushen SJ, Power DG, Teo MY et al. (2014) Body composition by computed tomography as a predictor of toxicity in patients with renal cell carcinoma treated with sunitinib. Am J Clin Oncol (In the Press).
20. Martin L, Birdsell L, Macdonald N et al. (2013) Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol 31, 1539-1547.
21. von Haehling S, Morley JE &Anker SD (2010) An overview of sarcopenia: facts and numbers on prevalence and clinical impact. J Cachexia, Sarcopenia Muscle 1, 129-133.
22. Prado CM, Wells JC, Smith SR et al. (2012) Sarcopenic obesity: a critical appraisal of the current evidence. Clin Nutr 31, 583-601.
23. Fearon K, Strasser F, Anker SD et al. (2011) Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 12, 489-495.
24. Tan BH, Birdsell LA &Martin L (2009) Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin Cancer Res 15, 6973-6979.
25. Silva AM, Shen W, Heo M et al. (2010) Ethnicity-related skeletal muscle differences across the lifespan. Am J Hum Biol 22, 76-82.
26. Baumgartner RN, Koehler KM, Gallagher D et al. (1998) Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol 147, 755-763.
27. Mourtzakis M, Prado CMM, Lieffers JR et al. (2008) A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab 33, 997-1006.
28. Anandavadivelan P, Brismar TB, Nilsson M et al. (2015) Sarcopenic obesity: a probable risk factor for dose limiting toxicity during neo-adjuvant chemotherapy in oesophageal cancer patients. Clin Nutr (epublication ahead of print version).
29. Lodewick TM, van Nijnatten TJ, van Dam RM et al. (2015) Are sarcopenia, obesity and sarcopenic obesity predictive of outcome in patients with colorectal liver metastases? HPB 17, 438-446.
30. Prado CM, Baracos VE, McCargar LJ et al. (2007) Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin Cancer Res 13, 3264-3268.
31. Prado CM (2013) Body composition in chemotherapy: the promising role of CT scans. Curr Opin Clin Nutr Metab Care 16, 525-533.
32. Prado CM, Maia YL, Ormsbee M et al. (2013) Assessment of nutritional status in cancer \-The relationship between body composition and pharmacokinetics. Anticancer Agents Med Chem 13, 1197-1203.
33. Prado CM, Lima IS, Baracos VE et al. (2011) An exploratory study of body composition as a determinant of epirubicin pharmacokinetics and toxicity. Cancer Chemother Pharmacol 67, 93-101.
34. Prado CM, Baracos VE, Xiao J et al. (2014) The association between body composition and toxicities from the combination of Doxil and trabectedin in patients with advanced relapsed ovarian cancer. Appl Physiol Nutr Metab 39, 693-698.
35. Narjoz C, Cessot A, Thomas-Schoemann A et al. (2015) Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients. Invest New Drugs 33, 257-268.
36. Prado CM, Antoun S, Sawyer MB et al. (2011) Two faces of drug therapy in cancer: drug-related lean tissue loss and its adverse consequences to survival and toxicity. Curr Opin Clin Nutr Metab Care 14, 250-254.
37. Antoun S, Birdsell L, Sawyer MB et al. (2010) Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study. J Clin Oncol 28, 1054-1060.
38. Alberta Health Services. A Study Comparing Chemotherapy Dosing Based on Either Standard Body Surface Area or Lean Body Mass in Patients With Advanced Lung Cancer. ClinicalTrialsgov [Internet] Bethesda (MD): National Library of Medicine (US)
39. Stene GB, Helbostad JL, Amundsen T et al. (2015) Changes in skeletal muscle mass during palliative chemotherapy in patients with advanced lung cancer. Acta Oncol 54, 340-348.
40. Meza-Junco J, Montano-Loza AJ, Baracos VE et al. (2013) Sarcopenia as a prognostic index of nutritional status in concurrent cirrhosis and hepatocellular carcinoma. J Clin Gastroenterol 47, 861-870.
41. Prado CMM, Mourtzakis M, Baracos V et al. (2010) Overweight and obese patients with solid tumors may have sarcopenia, poor prognosis and early features of cachexia. Int J Body Compos Res 8, 7-15.
42. Prado CM, Baracos VE, McCargar LJ et al. (2009) Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res 15, 2920-2926.
43. Lanic H, Kraut-Tauzia J, Modzelewski R et al. (2014) Sarcopenia is an independent prognostic factor in elderly patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Leuk Lymphoma 55, 817-823.
44. Miyamoto Y, Baba Y, Sakamoto Y et al. (2015) Sarcopenia is a negative prognostic factor after curative resection of colorectal cancer. Ann Surg Oncol 22, 2663-2668.
45. Miyamoto Y, Baba Y, Sakamoto Y et al. (2015) Negative impact of skeletal muscle loss after systemic chemotherapy in patients with unresectable colorectal cancer. PLoS ONE 10, e0129742.
46. Fukushima H, Yokoyama M, Nakanishi Y et al. (2015) Sarcopenia as a prognostic biomarker of advanced urothelial carcinoma. PLoS ONE 10, e0115895.
47. Voron T, Tselikas L, Pietrasz D et al. (2014) Sarcopenia impacts on short-and long-term results of hepatectomy for hepatocellular carcinoma. Ann Surg 261, 1173-1183.
48. Sharma P, Zargar-Shoshtari K, Caracciolo JT et al. (2015) Sarcopenia as a predictor of overall survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. Urol Oncol 33, 339 e17-e23.
49. Reisinger KW, Bosmans JW, UittenbogaartMet al. (2015) Loss of skeletal muscle mass during neoadjuvant chemoradiotherapy predicts postoperative mortality in esophageal cancer surgery. Ann Surg Oncol 22, 4445-4452.
50. Okumura S, Kaido T, Hamaguchi Y et al. (2015) Impact of preoperative quality as well as quantity of skeletal muscle on survival after resection of pancreatic cancer. Surgery 157, 1088-1098.
51. Reisinger KW, van Vugt JL, Tegels JJ et al. (2015) Functional compromise reflected by sarcopenia, frailty, and nutritional depletion predicts adverse postoperative outcome after colorectal cancer surgery. Ann Surg 261, 345-352.
52. Peng PD, van Vledder MG, Tsai S et al. (2011) Sarcopenia negatively impacts short-term outcomes in patients undergoing hepatic resection for colorectal liver metastasis. HPB 13, 439-446.
53. Ida S, Watanabe M, Yoshida N et al. (2015) Sarcopenia is a predictor of postoperative respiratory complications in patients with esophageal cancer. Ann Surg Oncol 22, 4432-4437.
54. Joglekar S, Asghar A, Mott SL et al. (2015) Sarcopenia is an independent predictor of complications following pancreatectomy for adenocarcinoma. J Surg Oncol 111, 771-775.
55. van Vugt JL, Braam HJ, van Oudheusden TR et al. (2015) Skeletal muscle depletion is associated with severe postoperative complications in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol 22, 3625-3631. doi: 10.1245/ s10434-015-4429-z.
56. Di Sebastiano KM &Mourtzakis M (2012) A critical evaluation of body composition modalities used to assess adipose and skeletal muscle tissue in cancer. Appl Physiol Nutr Metab 37, 811-821.
57. Tsai HK, D'Amico AV, Sadetsky N et al. (2007) Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 99, 1516-1524.
58. Demark-Wahnefried W, Peterson BL, Winer EP et al. (2001) Changes in weight, body composition, and factors influencing energy balance among premenopausal breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 19, 2381-2389.
59. Aubrey J, Esfandiari N, Baracos VE et al. (2014) Measurement of skeletal muscle radiation attenuation and basis of its biological variation. Acta Physiol 210, 489-497.
60. Sabel MS, Lee J, Cai S et al. (2011) Sarcopenia as a prognostic factor among patients with stage III melanoma. Ann Surg Oncol 18, 3579-3585.
61. Prado CM, Sawyer MB, Ghosh S et al. (2013) Central tenet of cancer cachexia therapy: do patients with advanced cancer have exploitable anabolic potential? Am J Clin Nutr 98, 1012-1019.
62. Baracos VE (2014) Skeletal muscle anabolism in patients with advanced cancer. Lancet Oncol. doi: 10.1016/S1470-2045(14)71185-4
63. Dobs AS, Boccia RV, Croot CC et al. (2013) Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial. Lancet Oncol 14, 335-345.
64. Garcia JM, Boccia RV, Graham CD et al. (2014) Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebocontrolled, double-blind trials. Lancet Oncol 16, 108-116.
65. Garcia JM, Boccia RV, Graham CD et al. (2015) Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebocontrolled, double-blind trials. Lancet Oncol 16, 108-116.
66. Deutz NE, Safar A, Schutzler S et al. (2011) Muscle protein synthesis in cancer patients can be stimulated with a specially formulated medical food. Clin Nutr (Edinburgh, Scotland) 30, 759-768.
67. Winter A, MacAdams J &Chevalier S (2012) Normal protein anabolic response to hyperaminoacidemia in insulinresistant patients with lung cancer cachexia. Clin Nutr 31, 765-773.
68. MacDonald AJ, Johns N, Stephens NA et al. (2014) Habitual myofibrillar protein synthesis is normal in patients with upper GI cancer cachexia. Clin Cancer Res 21, 1734-1740.
69. Hutton JL, Martin L, Field CJ et al. (2006) Dietary patterns in patients with advanced cancer: implications for anorexia-cachexia therapy. Am J Clin Nutr 84, 1163-1170.
70. Institute of Medicine (2005) Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein and Amino Acids (Macronutrients). Washington: National Academies Press.
71. Martin C (2000) Calorie, protein, fluid, and micronutrient requirements. In The Clinical Guide to Oncology Nutrition, p. 270. [PD McCallum and CG Polisena, editors]. Chicago: American dietetic association.
72. Bozzetti F (2013) Nutritional support of the oncology patient. Crit Rev Oncol Hematol 87, 172-200.
73. Arends J, Bodoky G, Bozzetti F et al. (2006) ESPEN guidelines on enteral nutrition: non-surgical oncology. Clin Nutr (Edinburgh, Scotland) 25, 245-259.
74. Prado CM, Lieffers JR, Bergsten G et al. (2012) Dietary patterns of patients with advanced lung or colorectal cancer. Can J Diet Pract Res 73, e298-e303.
75. Prado CMM, Lieffers JR, Bowthorpe L et al. (2013) Sarcopenia and physical function: in overweight patients with advanced cancer. Can J Diet Pract Res 74, 69-74.
76. Gonzalez MC, Pastore CA, Orlandi SP et al. (2014) Obesity paradox in cancer: new insights provided by body composition. Am J Clin Nutr 99, 999-1005.
77. Mir O, Coriat R, Blanchet B et al. (2012) Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma. PLoS ONE 7, e37563.
78. Huillard O, Mir O, Peyromaure M et al. (2013) Sarcopenia and body mass index predict sunitinib-induced early doselimiting toxicities in renal cancer patients. Br J Cancer 108, 1034-1041.
79. Massicotte MH, Borget I, Broutin S et al. (2013) Body composition variation and impact of low skeletal muscle mass in patients with advanced medullary thyroid carcinoma treated with vandetanib: results from a placebocontrolled study. J Clin Endocrinol Metab 98, 2401-2408.
80. Barret M, Antoun S, Dalban C et al. (2014) Sarcopenia is linked to treatment toxicity in patients with metastatic colorectal cancer. Nutr Cancer 66, 583-589.
81. Moryoussef F, Dhooge M, Volet J et al. (2015) Reversible sarcopenia in patients with gastrointestinal stromal tumor treated with imatinib. J Cachexia, Sarcopenia Muscle 6, 343-350.
82. Tan BH, Brammer K, Randhawa N et al. (2015) Sarcopenia is associated with toxicity in patients undergoing neo-adjuvant chemotherapy for oesophago-gastric cancer. Eur J Surg Oncol: J Eur Soc Surg Oncol Br Assoc Surg Oncol 41, 333-338.